Skip to Content
  1. Authors
  2. Kelsey Tsai

Kelsey Tsai

Kelsey Tsai is an equity analyst for Morningstar.


Though we've lowered our fair-value estimate of the drugmaker after it announced that it has stopped development of a key drug, we still believe in the potential of Alnylam’s remaining pipeline.